A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors

MLA

Nashat Y. Gabrail, et al. “A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors.” Journal of Clinical Oncology, vol. 40, Feb. 2022, p. TPS375. EBSCOhost, https://doi.org/10.1200/jco.2022.40.4_suppl.tps375.

APA

Nashat Y. Gabrail, Anthony Tolcher, Olatunji B. Alese, Michael Cecchini, Patel Manish, Haeseong Park, Jordan Berlin, Erika P. Hamilton, Yingjie Huang, Lingmin Lu, Jianming Wang, Michael Shi, & Ming F. Tong. (2022). A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal of Clinical Oncology, 40, TPS375. https://doi.org/10.1200/jco.2022.40.4_suppl.tps375

Chicago

Nashat Y. Gabrail, Anthony Tolcher, Olatunji B. Alese, Michael Cecchini, Patel Manish, Haeseong Park, Jordan Berlin, et al. 2022. “A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors.” Journal of Clinical Oncology 40 (February): TPS375. doi:10.1200/jco.2022.40.4_suppl.tps375.